Beyond monoamines: neurosteroid modulation of extrasynaptic GABA-A receptors by zuranolone and brexanolone in postpartum depression

Introduction: Postpartum depression is a disabling perinatal mood disorder associated with significant maternal functional impairment and adverse maternal–infant outcomes, for which limitations of monoaminergic frameworks have shifted attention toward GABAergic dysfunction as key pathophysiological mechanism, alongside neuroendocrine and stress-related system alterations [1][2]. Abrupt declines in allopregnanolone following childbirth may impair δ-subunit–containing extrasynaptic GABA-A receptor–mediated tonic inhibition, resulting in dysregulated excitation–inhibition balance in neural circuits governing emotional processing and stress responsivity. This links endocrine transitions to instability in affective networks. Furthermore emerging evidence suggests that individual variability in neurosteroid sensitivity may interact with genetic predisposition and environmental stressors to shape vulnerability trajectories across the perinatal period. Aims: We hypothesize that neurosteroid-based treatments, namely brexanolone and zuranolone, exert rapid antidepressant effects by restoring extrasynaptic GABA-A receptor function and stabilizing network activity.

Methods: A narrative literature review was conducted using PubMed focusing on English-language studies published between 2022 and 2025. Search terms included “brexanolone,” “zuranolone,” “allopregnanolone,” “GABA-A receptors,” “extrasynaptic inhibition,” and “postpartum depression.” Key evidence included studies regarding neurosteroid modulation and tonic inhibition, as well as clinical trials assessing efficacy and safety in perinatal populations. Evidence was synthesized qualitatively, integrating mechanistic and clinical findings.

Results: Brexanolone and zuranolone are synthetic analogues of allopregnanolone that act as positive allosteric modulators of GABA-A receptors, enhancing receptor sensitivity to endogenous GABA, with preferential activity at δ-subunit–containing extrasynaptic receptors that mediate tonic inhibition and regulate baseline neuronal excitability in limbic and cortical circuits involved in emotional processing [3][4]. Preclinical studies show that these agents increase tonic inhibitory currents and reverse stress- and neurosteroid withdrawal–induced reductions in GABAergic tone, leading to normalization of neuronal excitability. At the circuit level, these effects have been observed in the amygdala, hippocampus, and medial prefrontal cortex, which are implicated in affect regulation. This mechanism is consistent with their rapid clinical antidepressant effects, typically observed within 24–72 hours, which is substantially faster than conventional monoaminergic antidepressants, which can significantly affect mother–infant bonding, safety, and functioning [5]. Brexanolone requires a 60-hour intravenous infusion, whereas zuranolone is orally administered, with both having demonstrated efficacy in reducing depressive and anxiety symptoms in postpartum populations, and both associated with sedation, somnolence, and dizziness as the most common adverse effects [3][4][5].

Conclusions: Brexanolone and zuranolone provide compelling clinical support for a neurosteroid-based model of postpartum depression, demonstrating that rapid restoration of extrasynaptic GABA-A receptor–mediated tonic inhibition can stabilize affective circuit dysfunction following childbirth. Despite these advances, a critical knowledge gap remains in identifying precise biomarkers of neurosteroid sensitivity and predicting individual treatment response. Addressing this gap will be essential to translate this mechanistic framework into personalized, circuit-informed interventions. Ultimately, targeting neurosteroid modulation reframes postpartum depression as a rapidly reversible disorder of excitation–inhibition imbalance, with significant implications for the future of mood disorder therapeutics, particularly in clinical practice settings.

References

1. Patterson R, Balan I, Morrow AL, Meltzer-Brody S. Novel neurosteroid therapeutics for post-partum depression: perspectives on clinical trials, program development, active research, and future directions. Neuropsychopharmacology. 2024 Jan;49(1):67-72
2. Serretti A. Rapid-acting NMDA and GABAergic Modulators in Mood Disorders: From Synaptic Mechanisms to Clinical Practice. Clin Psychopharmacol Neurosci. 2025 Nov 30;23(4):527-541
3. Sonmez D, Hocaoglu C. Current Developments in the Treatment of Postpartum Depression: Zuranolone. Eurasian J Med. 2024 Oct 23;56(3):199-204
4. Arifunhera J, Mirunalini R. An update on the pharmacotherapy of postpartum depression. Int J Gynaecol Obstet. 2025 Mar;168(3):933-943
5. Barrett M, Hettema J, Youngman C, Wilkinson ST, Dalthorp R. Real-World Outcomes of Brexanolone to Treat Postpartum Depression. Womens Health Rep (New Rochelle). 2025 Oct 6;6(1):1081-1091